StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE), Astellas Pharma Inc. Reports Amendments to Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide
August 22, 2018 5:01 PM
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced amendments to the protocols for two registrational Phase 3 trials ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
August 22, 2018 5:00 PM
Exclusive: Pharma sector warns Saudis on German drug curbs
August 22, 2018 10:29 AM
Pre-Open Movers 8/22: (EXAS) (NEWA) (LZB) Higher; (SMCI) (NBEV) (GSM) Lower (more...)
August 22, 2018 9:26 AM
Exact Sciences (EXAS) Set to Open Higher by 20% Following Promotional Agreement with Pfizer (PFE) for Cologuard
August 22, 2018 8:42 AM
Exact Sciences (EXAS) Announces U.S. Promotional Agreement with Pfizer (PFE) for Cologuard
August 22, 2018 6:09 AM
Deutsche Bank Raises Pfizer (PFE) PT Prior To tafamidis Data
August 21, 2018 6:30 AM
U.S. health secretary says agency can eliminate drug rebates
August 20, 2018 7:06 AM